Patient's origin and lifestyle associated with CTX-M-Producing Escherichia coli: A Case-Control-Control study

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Nicolas Chanoine, Marie Hélène ^a,b,c   Jarlier, Vincent ^d,e   Robert, Jérôme ^d,e   Arlet, Guillaume ^f   Drieux, Laurence ^e,g   Leflon Guibout, Véronique ^a   Laouénan, Cédric ^c,h   Larroque, Béatrice ^a   Caro, Valérie ⁱ   Mentré, France ^c,h  

^a BEAUJON HOSPITAL   (France)

^b Faculte de Medecine D Diderot   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f HÔPITAL TENON   (France)

^g HÔPITAL CHARLES FOIX   (France)

^h BICHAT HOSPITAL   (France)

ⁱ INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE CTX M; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; BIRTHPLACE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; EMPLOYMENT STATUS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ETHNICITY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; FRANCE; GEOGRAPHIC ORIGIN; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; INFANT; LENGTH OF STAY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHUMAN; RAW MEAT; URINARY TRACT INFECTION; DISEASE PREDISPOSITION; ETHNIC GROUP; ETHNOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MULTIDRUG RESISTANCE; PHYSIOLOGY; RISK FACTOR; STATISTICS;

ESCHERICHIA COLI;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAMASES; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ETHNIC GROUPS; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84856379047     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030498     Document Type: Article

References (35)

1. Russo TA, Johnson JR, (2003) Medical and economic impact of extraintestinal infections due to Escherichia coli: an overlook epidemic. Microbes Infect 5: 449-456.
2. Pitout JD, Laupland KB, (2008) Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8: 159-166.
3. Bonnet R, (2004) Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48: 1-14.
4. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, et al. (2008) Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61: 273-281.
5. Rogers BA, Sidjabat HE, Paterson DL, (2011) Escherichia coli 025b-ST131: a pandemic multiresistant, community-associated strain. J Antimicrob Chemother 66: 1-14.
6. Meunier D, Jouy E, Lazizzera C, Kobisch M, Madec J-Y, (2006) CTX-M-1 and CTX-M-15 type β-lactamases in clinical Escherichia coli isolates recovered from food-producing animals in France. Int J Antimicrob Agents 28: 402-407.
7. Pomba C, da Fonseca JD, Baptista BC, Correia JD, Martinez-Martinez L, (2009) Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6′)-Ib-cr genes in a dog. Antimicrob Agents Chemother 53: 327-328.
8. Dhanji H, Murphy NM, Akhigbe C, Doumith M, Hope R, et al. (2010) Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water. J Antimicrob Chemother 66: 512-516.
9. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD, (2008) Community-onset extended-spectrum β-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 57: 441-448.
10. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, et al. (2007) Clinical and molecular epidemiology of community-onset, extended spectrum β-lactamase-producing Escherichia coli in Thailand: a case-case-control study. Am J Infect Control 35: 606-612.
11. Iabadene H, Messai Y, Ammari H, Ramdani-Bouguessa N, Lounes S, et al. (2008) Dissemination of ESBL and Qnr determinants in Enterobacter cloacae in Algeria. J Antimicrob Chemother 62: 133-136.
12. Li B, Sun JY, Liu QZ, Han LZ, Huang XH, et al. (2011) High prevalence of CTX-M β-lactamases in feacal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis 43: 170-174.
13. Mamlouk K, Boutiba-Ben Boubaker I, Gautier V, Vimont S, Picard B, et al. (2006) Emergence and outbreaks of CTX-M β-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains in a Tunisian hospital. J Clin Microbiol 44: 4049-4056.
14. Valverde A, Grill F, Coque TM, Pintado V, Baquero F, et al. (2008) High rate of intestinal colonization with extended-spectrum-β-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 46: 2796-2799.
15. Rooney PJ, O'Leary MC, Loughrey AC, McCalmont M, Smyth B, et al. (2009) Nursing homes as a reservoir of extended-spectrum β-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 64: 635-641.
16. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD, (2008) Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 14: 1041-1047.
17. Moor CT, Roberts SA, Simmons G, Briggs S, Morris AJ, et al. (2008) Extended-spectrum β-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect 68: 355-362.
18. Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, et al. (2011) Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 55: 3485-3490.
19. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Cisneros JM, et al. (2010) Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-β-lactamase-producing Escherichia coli. J Clin Microbiol 48: 1726-1731.
20. Wu UI, Yang CS, Chen WC, Chen YC, Chang SC, (2010) Risk factors for bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. J Microbiol Immunol Infect 43: 310-316.
21. Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtas M, et al. (2008) Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother 20: 581-585.
22. Lopez-Cerero L, Egea P, Serrano L, Navarro D, Mora A, et al. (2011) Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum β-lactamase belonging to ST410 phylogroup A. Int J Antimicrob Agents 37: 365-367.
23. Overdevest I, Willemsen I, Rijnsburger M, Eustace A, Xu L, et al. (2011) Extended-spectrum β-lactamase genes of Escherichia coli in chicken meat and humans, the Netherlands. Emerg Infect Dis 17: 1216-1222.
24. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, et al. (2009) A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 49: 682-690.
25. Kang CI, Song JH, Chung DR, Peck KR, Ko KS, et al. (2010) Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 36: 284-287.
26. Lee DS, Lee CB, Lee S-J, (2010) Prevalence and risk factors for extended-spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol 51: 492-497.
27. Schoevaerdts D, Bogaerts P, Grimmelprez A, de Saint-Hubert M, Delaere B, et al. (2011) Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital. BMC Infect Dis 11: 12.
28. Serefhanoglu K, Turan H, Timurkaynak FE, Arslan H, (2009) Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance. Braz J Infect Dis 13: 403-407.
29. Harris AD, Karchmer TB, Carmeli Y, Samore MH, (2001) Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 32: 1055-1061.
30. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, et al. (2010) Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50: 40-48.
31. McCabe W, Jackson G, (1962) Gram negative bacteremia: I. Etiology and ecology. Arch Intern Med 110: 845-847.
32. Anonymous, (2003) Comité de l'Antibiogramme de la Société Française de Microbiologie Report 2003. Int J Antimicrob Agents 21: 364-391.
33. Jarlier V, Nicolas MH, Fournier G, Philippon A, (1988) Extended broad-spectrum β-lactamases conferring transferable resistance to newer ß-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 10: 867-878.
34. Leflon-Guibout V, Jurand C, Bonacorsi S, Espinasse F, Guelfi MC, et al. (2004) Emergence and spread of three clonally related virulent isolates of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosides and tetracycline in a French geriatric hospital. Antimicrob Agents Chemother 48: 3736-3742.
35. Nicolas-Chanoine MH, Jarlier V, "La Collégiale" de Bactériologie-Virologie-Hygiène Hospitalière de l'Assistance Publique HdP (2008) Extended-spectrum β-lactamases in long-term-care facilities. Clin Microbiol Infect 14: 111-116.